Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria
Launched by UNIVERSITY OF PAVIA · Dec 23, 2009
Trial Information
Current as of May 04, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • blood pressure \> 130/80 \<180/105 mmHg at the end of the wash-out
- • type 2 diabetes mellitus well controlled by medication and / or compliance with diet (HbA1c \<7%)
- • microalbuminuria in the upper range of normal (\> 200 \<300 mg/24 h)
- Exclusion Criteria:
- • Pregnancy, lactation or women of childbearing age
- • Sitting diastolic blood pressure e 105 mmHg or systolic pressure e 180 at the end of the period of wash-out
- • History of hypertensive encephalopathy or cerebrovascular accident within 6 months
- • Secondary hypertension
- • Heart Failure
- • Myocardial infarction within 6 months
- • Angina pectoris, clinically significant valvular disease or arrhythmia
- • Alteration indices of liver function or renal
- • Known hypersensitivity to ACE inhibitors
- • All other physiological or pathological condition in the opinion of the physician may affect the evaluation of the parameters under study
About University Of Pavia
The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, Pv, Italy
Patients applied
Trial Officials
Roberto Fogari, MD
Study Director
University of Pavia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials